Agomab Therapeutics
About Agomab Therapeutics
Agomab Therapeutics is a biotechnology company focused on developing fibrotic disease therapies, leveraging deep expertise in growth factor biology to target fibrosis across multiple organ systems. The company conducts research and clinical development, including ontunisertib (AGMB-129) and other growth factor–modulating therapies, with an emphasis on gastrointestinal and other fibrotic conditions. Headquartered in Antwerp, Belgium, Agomab integrates translational science with a patient-centered mission to restore organ function.
Recent News
STAT+: A Sign Biotech Is Back? Four Drugmakers Go Public, Raising Nearly $1 Billion in All
JPM26 Recap, Novo’s Oral Wegovy Soars as Lilly’s Orforglipron Is Delayed, IPOs Return
Agomab Anticipates $182M IPO as It Builds Fibrosis Pipeline
Agomab, SpyGlass Cap Biggest Week for Biotech IPOs Since 2021
Eikon Prices Its IPO, Seeking to Raise $318m
Agomab and SpyGlass File for IPOs as Investor Enthusiasm Builds After JPM
2026 IPO Train Keeps Chugging as AgomAb, SpyGlass Eye Nasdaq Debut
Three More Biotechs Price Their Nasdaq IPOs
